Abstract

Objective: Uterine serous carcinoma (USC) is an aggressive subtype of endometrial carcinoma characterized by frequent TP53 mutations (>90%), often concomitantly with oncogenic mutations or amplifications that can increase replication stress. We hypothesized that USCs would therefore be uniquely sensitive to further interference of cell cycle regulation by Wee1 inhibition. This 2-stage single-arm phase 2 study was conducted to assess the activity of the oral Wee1 inhibitor adavosertib as monotherapy in recurrent USCs.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call